安罗替尼治疗恶性肿瘤的临床进展  

Clinical progress of anrotinib in the treatment of malignant tumor

作　　者：张帅[1] 王艳[1] ZHANG Shuai;WANG Yan(Harbin Medical University Cancer Hospital,Heilongjiang Harbin 150081,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院,黑龙江哈尔滨150081

出　　处：《现代肿瘤医学》2023年第19期3697-3701,共5页Journal of Modern Oncology

摘　　要：安罗替尼(AL3818,Anlotinib Hydrochloride)是我国自主研发的新型小分子多靶点酪氨酸激酶抑制剂(tyrosine kinase inhibitor,TKI),治疗靶点包括血管内皮细胞生长因子受体(vascular endothelial cell growth factor receptor,VEGFR)、血小板衍生生长因子受体(patelet-derived growth factor receptor,PDGFR)、成纤维生长因子受体(fibroblast growth factor receptor,FGFR),能够在抑制肿瘤血管生成的同时抑制肿瘤生长,且不良反应发生率较低,患者耐受情况好,可提高患者的生存质量。根据各项临床研究结果,安罗替尼已经获得晚期非小细胞肺癌、小细胞肺癌、软组织肉瘤、食管鳞癌和甲状腺髓样癌的中国临床肿瘤学会(Chinese Society of Clinical Oncology,CSCO)指南推荐,同时在肾癌、肝癌等多个瘤种领域中进行了积极探索。本文就安罗替尼的作用机制、临床研究、安全性等方面的最新临床进展进行综述,为后续的研究提供参考。Anlotinib(AL3818,Anlotinib Hydrochloride)is a new type of small molecule multi-target tyrosine kinase inhibitor(TKI)independently developed in China.Therapeutic targets of anlotinib include vascular endothelial cell growth factor receptor(VEGFR),patelet-derived growth factor receptor(PDGFR)and fibroblast growth factor receptor(FGFR).Anlotinib can inhibit tumor growth while suppressing tumor angiogenesis,and has fewer adverse reactions and tolerated by patients.Based on the results of various clinical studies,anlotinib has been recommended by the Chinese Society of Clinical Oncology(CSCO)guidelines for advanced non-small cell lung cancer,small cell lung cancer,soft tissue sarcoma,esophageal squamous cell carcinoma and medullary thyroid carcinoma,and has actively explored multiple tumor fields such as kidney cancer and liver cancer.This article reviews the latest clinical advances in the mechanism of action,clinical research,and safety of anlotinib,and provides a reference for subsequent research.

关 键 词：安罗替尼 酪氨酸激酶抑制剂 分子靶向药物 抗血管生成 

分 类 号：R730.5[医药卫生—肿瘤]